The research record · Doses & routes
Sermorelin Dosage as Documented in the Research Literature
What was administered, to which population, by which route — charted from the studies, not prescribed for anyone.
Start here
This page maps the sermorelin dosage figures that appear in published studies — and only as study facts. It does not tell anyone what to take. Doses are reported the way researchers reported them: a specific amount, given to a specific group of people, by a specific route (usually an injection under the skin). The most-cited numbers come from a children's growth study, an aging study in older men, and pharmacokinetic testing. Read them as a record of how the science was run, with the units and the population attached to every figure.
Research doses on record
The sermorelin dosage figures in the literature cluster by study type. In the pediatric growth-hormone-deficiency efficacy study, GHRH(1-29) was administered subcutaneously at 30 mcg/kg/day at bedtime [1]. In aging research, healthy older men received 0.5 mg and 1 mg subcutaneously twice daily for 14 days [2]. In pharmacokinetic work, intravenous doses of 0.25-2 mcg/kg elicited growth hormone release in healthy men, with maximal release at 1-2 mcg/kg [3]. Diagnostically, a single intravenous bolus (commonly around 1 mcg/kg) was historically used to test pituitary growth hormone reserve.
Each of these is a study parameter, not a recommendation. The doses differ because the purposes differ — a daily growth-promoting regimen in children, a short reversal study in older men, an acute provocation test of the pituitary. None of them is offered here as guidance for any individual.
Why bedtime dosing appears in the studies
Several studies timed administration to the evening, and the reason is physiologic. The largest natural growth hormone pulse occurs during slow-wave sleep, so dosing before bedtime aligns the stimulus with the body's own rhythm. The pediatric efficacy study administered GHRH(1-29) subcutaneously at bedtime [1], and the GHRH-analog cognition trial dosed before bedtime [6]. This reflects how the trials were designed to work with endogenous pulsatility — it is not a dosing instruction for any individual.
Handling, reconstitution, and stability
Lyophilized sermorelin acetate is reconstituted with sterile diluent; once reconstituted, it is typically refrigerated, because aqueous peptide solutions are susceptible to degradation, which is why GHRH(1-29) is supplied as a freeze-dried powder [3]. Compounded preparations are prepared under USP <797> sterile-compounding standards. Route choice follows the pharmacokinetics: subcutaneous injection is primary, intravenous appears in diagnostic and PK studies, and intranasal delivery was tested historically but achieved only about 3-5% bioavailability [3]. This describes laboratory and compounding handling, not self-administration guidance.
Does sermorelin need to be refrigerated?
In the research literature, sermorelin acetate is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions are prone to degradation. It is reconstituted with a sterile diluent, and once reconstituted it is typically refrigerated [3]. Compounded preparations are made under USP <797> sterile-compounding standards. This describes laboratory and compounding handling, not self-administration guidance.